Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease
NCT02015793
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn's Disease
Interventions
BIOLOGICAL:
Adalimumab
BIOLOGICAL:
Placebo for adalimumab
Sponsor
AbbVie